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OBJECTIVE—Results from the Diabetes Control Complications
Trial (DCCT) and the subsequent Epidemiology of Diabetes
Interventions and Complications (EDIC) Study and more re-
cently from the U.K. Prospective Diabetes Study (UKPDS) have
revealed that the deleterious end-organ effects that occurred in
both conventional and more aggressively treated subjects con-
tinued to operate 5 years after the patients had returned to
usual glycemic control and is interpreted as a legacy of past
glycemia known as “hyperglycemic memory.” We have hypothe-
sized that transient hyperglycemia mediates persistent gene-
activating events attributed to changes in epigenetic information.
RESEARCH DESIGN AND METHODS—Models of transient
hyperglycemia were used to link NFB-p65 gene expression with
H3K4 and H3K9 modiﬁcations mediated by the histone methyl-
transferases (Set7 and SuV39h1) and the lysine-speciﬁc demeth-
ylase (LSD1) by the immunopuriﬁcation of soluble NFB-p65
chromatin.
RESULTS—The sustained upregulation of the NFB-p65 gene as
a result of ambient or prior hyperglycemia was associated with
increased H3K4m1 but not H3K4m2 or H3K4m3. Furthermore,
glucose was shown to have other epigenetic effects, including the
suppression of H3K9m2 and H3K9m3 methylation on the p65
promoter. Finally, there was increased recruitment of the re-
cently identiﬁed histone demethylase LSD1 to the p65 promoter
as a result of prior hyperglycemia.
CONCLUSIONS—These studies indicate that the active tran-
scriptional state of the NFB-p65 gene is linked with persisting
epigenetic marks such as enhanced H3K4 and reduced H3K9
methylation, which appear to occur as a result of effects of the
methyl-writing and methyl-erasing histone enzymes. Diabetes
58:1229–1236, 2009
V
ascular complications are the major source of
morbidity and mortality in diabetes and are con-
sidered, based on both epidemiological data and
from more mechanistic studies, to occur primar-
ily as a result of the long-term deleterious effects of
hyperglycemia. Interestingly, these vascular complications
often persist and may progress despite improved glucose
control, possibly as a result of prior episodes of hypergly-
cemia. Results in both type 1 and type 2 diabetes, as
observed in the Diabetes Control and Complications Trial
(DCCT)/Epidemiology of Diabetes Interventions and Com-
plications (EDIC) Study and in the recent follow-up of the
U.K. Prospective Diabetes Study (UKPDS), have revealed
that end-organ effects that occurred in both conventional
and intensiﬁed glycemic control groups continued to op-
erate 5 years after the patients had returned to their
usual level of glycemic control (1,2). These studies suggest
that the injurious effects of exposure to high glucose levels
persist for many years after these episodes of altered
metabolic control and this is typically referred to as either
“hyperglycemic memory” (3) or the legacy effect (4).
Recently, several clinical trials, including the ADVANCE
(5) and ACCORD studies (6), failed to demonstrate that
intensiﬁed glycemic control for 3–5 years markedly re-
duced macrovascular complications, emphasizing the lack
of rapid reversibility of glucose-related vascular changes
by improved glycemic control. Indeed, such studies are
consistent with the view that previous episodes of tran-
sient hyperglycemia may induce longstanding deleterious
changes in the vasculature.
Until now, our view of the susceptibility to hyperglyce-
mia-induced vascular complications focused predomi-
nantly on genetic polymorphisms, but recent studies
exploring epigenetic mechanisms such as chromatin re-
modeling, histone modiﬁcations, and DNA methylation are
increasingly appreciated to be critical to the way we view
changes in gene activity. This gene-environment interac-
tion involving epigenetic changes may be particularly
relevant to the pathogenesis of diabetes complications (7)
and conferring epigenetic marks by speciﬁcally modulat-
ing histone methylation (8). In this study, we have ex-
tended these ﬁndings to characterize in more detail the
nature of histone methylation of the promoter region of
the NFB-p65 gene, which is upregulated in a sustained
manner in response to prior transient hyperglycemia (3).
These results highlight the importance of histone modiﬁ-
cations that control gene activity, which is linked with
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tained when the endothelial cell is out of its previous
hyperglycemic milieu.
RESEARCH DESIGN AND METHODS
In vitro studies
Cell culture conditions and treatments. Conﬂuent bovine aortic endothe-
lial cells were maintained in minimum essential medium (Gibco) containing
0.5% fetal bovine serum, nonessential amino acids (Gibco), and antibiotics
Gentamicin (Pﬁzer). Cells were incubated with minimum essential medium
with 5.5 mmol/l low glucose or minimum essential medium with 30 mmol/l
high glucose or 30 mmol/l mannitol for 16 h where stated.
Set7 shRNA knockdown. Human microvascular endothelial cells (HMECs)
were infected with MISSION shRNA-expressing lentiviral vectors targeted to
Set7 coding regions according to the user instructions (Sigma). The
sequence targeting Set7 corresponds to 5-CCAGATCCTTATGAATCA-
GAA-3 (TRCN0000078630). Cells transduced with MISSION Non-Target
shRNA Control Vector were used as controls. HMECs were seeded at 5  10
5
cells/dish in a 60-mm dish 20 h before infection, incubated with the lentivirus
for 2 days, followed by selection in puromycin (1 g/ml; Sigma) for 7 days. The
cells were examined by protein blots using anti-Set7 rabbit antibody.
Overexpression of Set7 in human endothelial cells. HMECs expressing
Set7 were created by retrovirus-mediated gene transfer as described previ-
ously (9). cDNAs encoding FLAG-tagged Set7 were inserted between the
BamHI and NotI sites of the retroviral vector pCX4neo (10) (a gift from Dr. T.
Akagi, KAN Research Institute, Kobe, Japan) to create pJS14. pJS14 or
pCX4neo was co-transfected with retrovirus packaging vectors (Takara) into
293T cells (10). Two days after transfection, culture supernatants were
collected and used as viral stocks. HMECs were seeded at 5  10
5 cells/dish
in a 60-mm dish 20 h before infection, incubated with the virus stock for 2
days, followed by selection in Geneticin (G418, 1 mg/ml; Invitrogen) for 7
days. The cells were then examined by protein blots using anti-FLAG M2
monoclonal antibody (Sigma) and anti-Set7 rabbit serum (a gift from Dr. P.L.
Jones, University of Illinois) (7).
Immunoprecipitation of FLAG-Set7. Cell lysates were prepared from cells
expressing FLAG-Set7 or from cells transduced with pCX4neo as a control.
The 1  10
7 cells were washed twice with ice-cold PBS and extracted with 600
l lysis buffer (50 mmol/l Tris HCl, pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA,
1% Triton X-100, and proteinase inhibitor). Lysate was incubated with anti-
FLAG M2 afﬁnity gel (Sigma) for2ha t4°C. Immunoprecipitates were washed
with Tris-buffered saline (50 mmol/l Tris HCl, pH 7.5, 150 mmol/l NaCl) three
times and then eluted with 3 FLAG peptide (Sigma) and analyzed by immuno-
blotting as well as measuring histone methyltransferase activity.
Histone methyltransferase activity assay. The histone methyltransferase
activity assay was performed according to the manufacturer’s (Upstate)
instructions. One of the following substrates was used for methyltransferase
reactions: 5 g recombinant histone H3 (Upstate) or 0.4 nmol of a biotin-
conjugated histone H3 peptide (amino acids 1–23), either K4 or R4 (Sigma).
Reactions were determined by spotting on P-81 paper (Upstate) and scintil-
lation counting.
Chromatin immunoprecipitation. Cells were treated with formaldehyde at
a 1% concentration for 10 min and then treated with glycine at 0.15 mol/l for
10 min. Cell pellets were resuspended in SDS lysis containing 1% SDS, 10
mmol/l EDTA, 50 mmol/l Tris, pH 8.1 (Upstate), and a protease inhibitor
cocktail (Roche). Cells were sonicated to shear chromatin to 700–300 bp in
length, resuspended in chromatin immunoprecipitation dilution buffer con-
taining 0.01% SDS, 1.1% Triton X-100, 1.2 mmol/l EDTA, 16.7 mmol/l Tris-HCl,
pH 8.1, and 167 mmol/l NaCl, and 15 l salmon sperm DNA-protein A agarose
(Upstate) was added and precleared. To the soluble chromatin fraction, the
following antibody of interest was added and incubated for a minimum of 8 h:
H3K4m1 (Abcam ab8895), H3K4m2 (Upstate 07030), H3K4m3 (Upstate 07473),
H3K9m1 (Abcam ab9045), H3K9m2 (Abcam ab7312–100), H3K9m3 (Abcam
ab8898), Set7 (a gift from Dr. P Jones, University of Illinois at Urbana-
Champaign), LSD1 (Upstate 05939), and Suv39h1 clone MG44 (Upstate 05615).
Immune complexes were collected with salmon sperm DNA-protein A agarose
and subsequently washed and eluted with buffer (1% SDS, 0.1 mol/l NaHCO3).
Protein-DNA cross-links were reversed overnight at 65°C and recovered by
phenol-chloroform extraction and ethanol precipitated at 20°C. Analysis of
chromatin immunoprecipitation DNA samples was performed by quantitative
PCR (qPCR) of the nuclear factor (NF)-B p65 promoter region (sequences
available on request). An input sample was used as an internal control for
variation in DNA between samples.
RNA isolation and ﬁrst-strand cDNA synthesis. Total RNA was ex-
tracted using Trizol preparation. Cells were subsequently treated with Turbo
DNAse (Ambion). First-strand cDNA synthesis from the puriﬁed mRNA was
performed using M-MLV Reverse Transcriptase (Invitrogen) according to the
manufacturer’s instructions. The NFB p65 gene was quantiﬁed using
qRT-PCR.
RT-PCR. PCR ampliﬁcation was performed using ABI Prism 7500; 2 pmol of
each forward and reverse primer was added to a total of 20 l reaction
containing 1 SYBR Green qPCR SuperMix-UDG and Rox Reference Dye
(Invitrogen). Reactions were incubated for 50°C for 2 min and 95°C for 10 min,
followed by 50 cycles of 95°C for 15 s and 60°C for 1 min.
In vivo studies
Animal model. Male apolipoprotein knockout (apoE KO) mice (backcrossed
20 times to a C57BL/6 background; Animal Resource Centre, Canning Vale,
WA, Australia) were housed at the Precinct Animal Centre, Baker IDI Heart
and Diabetes Institute, and studied according to guidelines of the National
Health and Medical Research Council of Australia. At week 7, mice were
rendered diabetic via ﬁve daily intraperitoneal injections of 55 mg  kg
1 
day
1 streptozotocin (MP Biomedicals, Eschwege, Germany), resulting in a
model of insulin deﬁciency (11). ApoE and apoE diabetic mice were moni-
tored for 20 weeks. In over 90% of mice injected with these ﬁve daily injections
of streptozotocin, plasma glucose levels were 20 mmol/l within the ﬁrst
week of the study. In all injected mice, plasma glucose levels were measured
every 2 weeks. This serial monitoring revealed that in a subgroup of mice
(20%), despite initially developing hyperglycemia, after 10–12 weeks,
these mice now had reduced plasma glucose levels (15 mmol/l) despite no
treatment, which remained decreased until the time of death at week 20. This
group was termed “previously hyperglycemic” (HG3NG) and was compared
to the control (NG3NG) and diabetic (HG3HG) mice. All these apoE KO
mice received standard mouse food and water ad libitum. Mice were culled by
euthanasia using an intraperitoneal injection of Euthal (10 mg/kg) (Delvet
Limited, Seven Hills, Australia) followed by exsanguination via cardiac
puncture. The excised aortas were placed in 10% neutral buffered formalin and
quantitated for lesion area before being processed for subsequent immuno-
histochemical analysis. In a subset of animals, aortas were snap-frozen in
liquid nitrogen and stored at 70°C for subsequent RNA extraction.
Metabolic parameters. Erythrocytes were collected at death for measure-
ment of glycated hemoglobin by high-performance liquid chromatography.
Plasma glucose levels were measured using an automated system (Abbott
Architect ci8200, Abbott Laboratories). At death, plasma lipids were measured
by an autoanalyzer (11).
Isolation of total RNA, synthesis of cDNA, and quantitative real-time
PCR. Gene expression of NFB p65, vascular adhesion molecule 1 (VCAM-1),
and macrophage chemoattractant protein 1 (MCP-1) were assessed by real-
time qPCR. This was performed using the TaqMan system based on real-time
detection of accumulated ﬂuorescence (ABI Prism 7500; Perkin-Elmer, PE
Applied Biosystems, Foster City, CA), as previously used by our group (12).
Brieﬂy, whole aorta was homogenized using the Ultra-Turrax (Janke & Kunkel
IKA, Labortechnik, Germany) in TRIZOL (Life Technologies, Gaithersburg,
MD), and total RNA was isolated. cDNA was synthesized with a reverse
transcriptase reaction using the Superscript First Strand Synthesis System for
RT-PCR (Life Technologies) with random hexamers, dNTPs, and total RNA
extracted from mouse aortas. To assess genomic DNA contamination, con-
trols without reverse transcriptase were included. Brieﬂy, gene-speciﬁc 5-
oligonucleotide primer, 3-oligonucleotide primer, and MGB FAM-probe
corresponding to each gene (sequences available upon request) were designed
using the software program Primer Express (PE Applied Biosystems). The
generation of amplicons was deﬁned as the point during cycling when
ampliﬁcation of the PCR product is ﬁrst detected above the threshold setting.
The RT-PCR took place with 500 nmol/l of forward and reverse primer and
50 nmol/l of FAM/MGB probe and VIC 18S ribosomal probe, in 1 Taqman
universal PCR master mix (PE Biosystems). Each sample was run and
analyzed in triplicate. Gene expression was normalized to 18S mRNA with
samples from the control (NG3NG) aorta used as the calibrator with a given
value of 1, and all other groups were compared with this calibrator group.
Plaque area quantitation. Plaque area was quantitated as described
previously (11). In brief, aortas removed from the mice were cleaned of excess
fat under a dissecting microscope and subsequently stained with Sudan
IV-Herxheimer’s solution (0.5% wt/vol) (Gurr, BDH Limited). Aortas were
dissected longitudinally; divided into arch, thoracic, and abdominal segments;
and pinned ﬂat onto wax. Images were acquired with a dissecting microscope
equipped with an Axiocam camera (Zeiss, Heidelberg, Germany). Total and
segmental (i.e., arch, thoracic, and abdominal) plaque area was quantitated as
the percentage area of aorta stained red (Adobe Photoshop v7.0).
Statistical analysis. Data are shown as means 	 SE. One-way nonparamet-
ric ANOVA for repeated measures followed by Fisher’s post hoc test was used
to compare treatment groups. Calculations were performed using GraphPad
Prism (Graphpad Software).
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Previous hyperglycemia is associated with persistent
gene activity and H3K4m1. We recently demonstrated
that transient hyperglycemia causes gene-activating
H3K4m1 marks associated with NFB-p65 gene expres-
sion (3). Despite these and other recent advances, under-
standing the complexity of H3K4 and H3K9 methylation
remains an important challenge. We show that transient
hyperglycemia induces long-lasting activation of the
NFB-p65 gene (Fig. 1A) and persistent changes in
H3K4m1 (Fig. 1B), which were not seen for H3K4m2 (Fig.
1C) and H3K4m3 (Fig. 1D). The epigenetic changes persist
for 6 days of subsequent normal glycemia. To differentiate
the role of glucose in endothelial cells, we also measured
the effect of transient hyperglycemia on the counteracting
cytokine, interleukin (IL)-10. Expression of the IL-10 gene
in bovine and human endothelial cells did not change after
transient exposure to hyperglycemia (data not shown).
Set7 mono-methylates H3K4 in human vascular cells.
Based on this speciﬁc change in H3K4m1, but not di-
methylation or tri-methylation, we postulated that the Set7
enzyme, previously reported to act as a histone mono-
methyltransferase, albeit in nonendothelial cells, might be
involved (13). Indeed, because the crystal structure of Set7
(13) indicates speciﬁcity for this enzyme as a mono-
methylase to its target K4 lysine of histone H3, we tested
puriﬁed Set7 expressed from human vascular cells. These
results show for the ﬁrst time that expressed Set7 pos-
sesses histone methyltransferase activity, as assayed by its
ability to methylate histone H3 (Fig. 1E). To determine
whether H3K4 is the unique methylation site of Set7
activity (14), histone methyltransferase activity of puriﬁed
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FIG. 1. Ambient and prior hyperglycemia sustains increased activating H3K4m1-associated Set7 enrichment on the NFkB-p65 gene in aortic
endothelial cells. A: Ambient and prior hyperglycemia sustains increased NFkB-p65 gene expression in bovine aortic endothelial cells. RNA was
extracted, and NFB-p65 mRNA levels were quantiﬁed by real-time RT-PCR (qRT-PCR) and normalized to the level of 18S. *P < 0.05 vs. low
glucose (LG) 16 h group. Mono-methylation is the predominant H3K4 mark after transient hyperglycemia. Bovine aortic endothelial cells were
exposed to glucose and soluble chromatin was immunopuriﬁed at the indicated times using H3K4m1 (B), H3K4m2 (C), and H3K4m3 (D)
antibodies. qPCR was used to measure the level of enrichment on the NFB-p65 promoter (400 bp from the 1 transcription start site). Error
bars represent SE. Samples were analyzed in triplicate, and data are presented as means  SE. *P < 0.05 vs. LG 16 h group, **P < 0.01 vs. LG
16 h group. E: Set7 associated histone methyltransferase activity of human FLAG tagged Set7 (Flag-Set7) overexpressed in human endothelial
cells and immunoprecipitated using anti-ﬂag antibody. The substrate used to determine methyltransferase activity was recombinant histone H3.
F: Lysine 4 of histone H3 (H3K4) is a major methylation site for the Set7 enzyme. Set7 was immunoprecipitated by anti-FLAG antibody in
overexpressed Set7 or control pCX4neo human endothelial cells. Substrates used to determine methyltransferase activity were synthesized
histone H3K4 and mutant H3R4 peptides. G: Aortic endothelial cells were exposed to glucose and soluble chromatin were immunopuriﬁed at the
indicated times with Set7 antibody, and qPCR was used to measure the level of enrichment on the NFB-p65 promoter. *P < 0.01 vs. LG 16 h
group. H: The osmolyte mannitol does not increase NFB-p65 mRNA levels. Samples were analyzed in triplicate, and data are presented as
means  SE. I: Mannitol does not increase Set7 association with the NFB-p65 promoter. Samples were analyzed in triplicate, and data are
presented as means  SE.
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DIABETES, VOL. 58, MAY 2009 1231Set7 was assayed using H3K4 and H3R4 as substrate
peptides (Fig. 1F). The results of these experiments indi-
cate that Set7 has speciﬁc H3K4 methylation activity and
mutation of the lysine residue to arginine (H3R4) elimi-
nates the ability of the peptide to serve as a substrate for
the Set7 histone methyltransferase.
Glucose-induced changes in H3K4m1 are related to
the recruitment of Set7. Because Set7 appears to be the
enzyme responsible for H3K4m1 in immortalized cancer
cell types (14) and is now conﬁrmed in endothelial cells
(Fig. 1E and F), we subsequently tested the hypothesis
that Set7 is mobilized to the NFB-p65 promoter to
maintain the active transcriptional state. Immunopuriﬁed
chromatin from bovine aortic endothelial cells exposed to
transient hyperglycemic conditions was associated with
sustained enrichment for Set7 on the NFB-p65 promoter
(P  0.05) in response to glucose (Fig. 1G). To exclude the
possibility that the effects are a result of osmotic stress,
cells were incubated in 30 mmol/l mannitol for 16 h and
returned to normoglycemia for 2, 4, or 6 days. Analysis of
NFB-p65 gene expression showed no increase in the p65
transcript in response to mannitol stimulation (Fig. 1H).
Chromatin immunoprecipitation analyses indicated no en-
richment of the Set7 enzyme on the NFB-p65 promoter
consistent with persisting epigenetic marks being medi-
ated by glucose (Fig. 1I).
Set7 knockdown attenuates glucose-induced p65
gene activity. Having established that Set7 has methyl-
transferase activity for H3K4 and speciﬁc recruitment to
the NFB-p65 gene, we next determined the functional
consequence of knockdown of Set7 on epigenetic persis-
tence of H3K4m1 marks and NFB-p65 gene expression
mediated by transient hyperglycemia. A protein blot of
Set7 in wild-type and knockdown (Set7KD) cells indicated
robust silencing by the shRNA to Set7 in endothelial cells
(Fig. 2A). Transient hyperglycemia failed to induce NFB-
p65 gene expression in Set7KD cells (Fig. 2B), suggesting
that this speciﬁc histone methyltransferase is required for
glucose-mediated gene activity. We also conﬁrmed that the
erasure of NFB-p65 gene expression depends on changes
in histone methylation mediated by Set7 (Fig. 2C). Parallel
experiments using H3K4m2 antibody were also performed
to illustrate the speciﬁcity of histone modiﬁcation with no
effect on H3K4m2 seen with Set7KD (Fig. 2D). We also
assessed IL-10 gene expression in Set7KD and wild-type
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FIG. 2. Erasure of the activating H3K4m1 mark on the NFB-p65 promoter in Set7 KD cells despite transient hyperglycemia. A: Protein blot of
Set7 knockdown in HMECs exposed to ambient and prior hyperglycemia for the indicated times. B: Ambient and prior hyperglycemia does not
sustain increased NFkB-p65 gene expression in Set7 KD cells. RNA was extracted, and NFB-p65 mRNA levels were quantiﬁed by real-time
RT-PCR (qRT-PCR) and normalized to the level of 18S. C: Knockdown of the Set7 enzyme rescinds H3K4m1 mark on the NFB-p65 promoter.
Samples were analyzed in triplicate, and data are presented as means  SE. *P < 0.05 vs. LG 16 h group. D: Set7 KD does not change the H3K4m2
mark on the NFB-p65 promoter. HMECs were exposed to glucose, and soluble chromatin was immunopuriﬁed at the indicated times for SuV39h1
(E), H3K9m1 (F), H3K9m2 (G), H3K9m3 (H), and LSD1 (I) antibodies. qPCR was used to measure the level of enrichment on the NFB-p65
promoter. Error bars represent SE. Samples were analyzed in triplicate, and data are presented as means  SE. *P < 0.05 vs. LG 16 h group.
HYPERGLYCEMIC MEMORY AND THE H3-LYSINE TAIL
1232 DIABETES, VOL. 58, MAY 2009cells. The knockdown of Set7 did not change IL-10 mRNA
levels in these cells (data not shown).
SuV39h1 has a conserved Set [Su(var)3–9, Enhancer-of-
zeste, Trithorax] catalytic domain that belongs to the
histone methyltransferase family and is capable of meth-
ylating lysine K9 of histone H3 (H3K9) to mediate tran-
scriptional repression. We ﬁrst determined whether
SuV39h1 was inversely correlated with NFB-p65 tran-
scription and a component of hyperglycemic memory.
Soluble chromatin fractions derived from cross-linked
HMECs were immunoprecipitated against SuV39h1 anti-
body and enrichment was compared with baseline glucose
controls by real-time PCR quantitation. Chromatin immu-
nopuriﬁcation analysis indicates that the co-repressor
SuV39h1 does not signiﬁcantly change on the p65 pro-
moter (Fig. 2E).
Transient hyperglycemia causes a sustained reduc-
tion of H3K9 methylation on the NFB-p65 promoter.
The degree of gene activation or inhibition is exquisitely
regulated by multiple histone marks mediated by histone
methyltransferase enzymes (15). Indeed, methylation of
H3K4 and H3K9 can both inhibit each other and can be
mutually antagonistic (14). Therefore, to further elucidate
the underlying regulatory mechanism of NFB-p65 gene
expression as a result of transient and prior hyperglycemia
in endothelial cells, we speciﬁcally investigated these
repressive H3K9 methylation marks. Endothelial cells
were incubated in high glucose for 16 h and then returned
to normoglycemic conditions for 2, 4, or 6 days and
analyzed for H3K9m1 (Fig. 2F). Chromatin immunopre-
cipitation measurements indicate that transient hypergly-
cemia causes a sustained reduction in both H3K9m2 (Fig.
2G) and H3K9m3 (Fig. 2H) on the NFB-p65 promoter.
Transient hyperglycemia induces recruitment of
LSD1 H3 demethylase. Although we have initially fo-
cused on various changes in histone methylation, it is
increasingly appreciated that methyl groups can be re-
moved or erased as a result of demethylation (16). Indeed,
until recently, it was believed that methyl groups could not
be removed and erased from histones. Recent experimen-
tal studies now show that demethylation is linked to both
transcriptional repression and activation events (17,18).
Lysine-speciﬁc demethylase 1 (LSD1) and Jumonji C
(JmjC) have recently been characterized as H3 demethy-
lases (19–22). LSD1 is a nuclear amine oxidase that uses
oxygen as an electron acceptor to reduce methylated
lysine to form lysine (20). LSD1 demethylates H3K4m1 and
H3K4m2 and is consistent with its role in removal of the
active methylation mark; LSD1 is found in co-repressor
complexes and promotes suppression of gene expression
(16). LSD1 is also associated with the activation of gene
expression and demethylation of H3K9m1 and H3K9m2
(19,21,23). The JmjC protein family speciﬁcally demethyl-
ates H3K9 and is associated with the activation of gene
expression (24,25). The preference for distinct H3K9 meth-
ylation erasure in the experiments we have performed
(Fig. 2E and F) prompted us to test the hypothesis that
demethylation at histone H3 lysine 9 might be associated
with the cooperative recruitment of LSD1 at the NFB p65
gene. The role of the LSD1 enzyme in response to transient
hyperglycemia is not well understood, and this is under-
scored by recent evidence suggesting the release of the
demethylase on active genes is inversely linked with
increased H3K4m2 (26). With these results in mind and our
experimental evidence indicating that transient hypergly-
cemia could be associated with increased gene-activating
H3K4m1 with no signiﬁcant change in H3K4m2 or
H3K4m3, we examined recruitment of LSD1 demethylase
to the p65 promoter in response to hyperglycemia. Results
shown in Fig. 2I indicate that transient hyperglycemia
enriches the demethylase, LSD1, on the NFB-p65 pro-
moter and that this is inversely correlated with H3K9
methylation, which is consistent with its role as a co-
activator of gene activity.
In vivo studies
Metabolic parameters. To explore the in vivo relevance
of these changes in p65 expression, we examined changes
in expression of NFB-p65 not only in a well-validated
model of diabetes-associated atherosclerosis, the diabetic
apoE KO mice (27), but also have evaluated these changes
in a group of mice where there has been a degree of 
-cell
recovery weeks after induction of diabetes, as has been
previously reported with respect to streptozocin in ro-
dents (28). This subgroup of mice has experienced a
period of hyperglycemia followed by a signiﬁcant period of
near-normoglycemia (HG3NG), allowing us to determine
if previous transient episodes of hyperglycemia can lead to
sustained upregulation of genes implicated in diabetic
vascular injury.
Glycated hemoglobin was increased signiﬁcantly in the
diabetic apoE KO group (17.6 	 0.4%, n  15) when
compared with the control apoE KO group (4.7 	 0.1%,
n  15). Both these parameters were decreased in the
previously hyperglycemic group but were still elevated
(6.4 	 0.8%, n  10), albeit modestly, when compared with
the control apoE KO group (P  0.05). Body weight was
signiﬁcantly decreased in the diabetic apoE KO group
(20.9 	 0.4 g) compared with control apoE KO mice
(30.7 	 0.3 g, P  0.01). Mice in the previously hypergly-
cemic group had a modest decrease in body weight (27.0 	
1.0 g) when compared with control apoE KO mice (P 
0.05) but not as low as seen in diabetic apoE KO mice (P 
0.01). Plasma lipids including total and LDL cholesterol
were increased in diabetic apoE KO mice but were similar
to control mice in the previously hyperglycemic animals
(total cholesterol, control 14.5 	 0.7 mmol/l [means 	 SE],
diabetic 33.0 	 4.6 mmol/l [P  0.01 vs. control], previ-
ously hyperglycemic 15.5 	 1.3 mmol/l [P  0.01 vs.
diabetic]; LDL cholesterol, control 10.4 	 0.6 mmol/l,
diabetic 27.2 	 4.4 mmol/l [P  0.01 vs. control], previ-
ously hyperglycemic 10.5 	 2.8 mmol/l [P  0.01 vs.
diabetic]).
Plaque area remained increased and NFB, VCAM,
and MCP-1 mRNA levels remained elevated in previ-
ously hyperglycemic mice. Plaque area was quantitated
as a percentage area of aorta stained red with Sudan IV.
Total plaque area was signiﬁcantly increased in diabetic
apoE mice (HG3HG) and was compared with control
apoE mice (NG3NG) (Table 1). Importantly, the greater-
than-threefold increase in plaque area was also seen in the
previously hyperglycemic (HG3NG) mice. When plaque
area was quantiﬁed in the three individual segments (arch,
thoracic, and abdominal region), the same pattern was
observed as for total plaque area with an increase in
plaque area at all three sites in diabetic mice and a similar
increase at these sites in the previously hyperglycemic
mice (Fig. 3). Aortic mRNA levels for NFB p65 were
signiﬁcantly upregulated in diabetic apoE KO mice when
compared with the apoE KO controls (Table 2). NFB p65
gene expression was also signiﬁcantly upregulated in the
aortas from the previously hyperglycemic mice. Gene
expression of two important mediators of atherosclerosis,
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NFB dependent—VCAM-1 (11) and MCP-1 (29)—were
also signiﬁcantly upregulated in the chronically diabetic
mice. This increase in MCP-1 and VCAM-1 mRNA levels
was also observed in the aortas from the previously
hyperglycemic mice (Table 2).
DISCUSSION
The novel ﬁndings described in these in vitro studies
represent a paradigm shift in understanding the relation-
ship between epigenetic change and hyperglycemic mem-
ory. Using endothelial cell models of transient and prior
hyperglycemia, we demonstrated that active NFB-p65
gene expression is linked to persisting epigenetic marks
that are maintained when the cell is removed from its
hyperglycemic environment. The evidence for this came
from cell culture experiments in which speciﬁed changes
in epigenetic information are associated with transcrip-
tional longevity. Three sets of experiments indicated that
the underlying regulatory mechanism of NFB-p65 gene
activity induced by hyperglycemia involve speciﬁc epige-
netic modiﬁcations. First, the persistence of NFB-p65
gene activation mediated by transient hyperglycemia is
associated with Set7 recruitment and H3K4 mono-methy-
lation, which could be overcome by somatic knockdown
of the Set7 methyl-lysine writer. Second, the consequent
increase in activating epigenetic marks is directly corre-
lated with distinct and persistent H3K9 demethylation
events. Finally, chromatin immunopuriﬁcation studies in-
dicate hyperglycemia-induced recruitment of the methyl-
lysine eraser, LSD1, occurs concomitantly with reduced
H3K9 methylation and increased NFB-p65 expression.
Although none of the experiments alone constitutes evi-
dence that any one epigenetic mark is solely important in
long-lived gene activity, taken together, the evidence
strongly suggests that changes in epigenetic information
are associated and potentially could partly explain the
phenomenon of “hyperglycemic memory.”
The importance of sustained effects of previous changes
in glucose levels is increasingly being appreciated as a
result of more recent ﬁndings from studies of vascular
TABLE 1
Total and arch plaque area was quantitated as a percentage area of aorta stained red with Sudan IV in control apoE KO, diabetic apoE
KO, and previously hyperglycemic apoE KO mice
n Total Arch Thoracic Abdominal
Control apoE KO (NG3NG) 10 3.0 	 0.5 8.0 	 0.5 1.2 	 0.3 1.1 	 0.3
Diabetic apoE KO (HG3HG) 10 13.0 	 1.0* 24.4 	 1.0* 8.7 	 1.0* 8.5 	 0.7*
Previously hyperglycemic apoE KO (HG3NG) 6 11.4 	 1.9* 21.3 	 2.1* 8.0 	 2.7* 8.2 	 1.8*
Data are means 	 SE. *P  0.05 compared with the control apoE KO group.
A
B
C
ARCH THOR ABDOM
FIG. 3. Plaque area remained increased in the previously hyperglyce-
mic mice. Atherosclerotic plaques in aorta staining in red with picro
sirus red solution in control apoE KO (A), diabetic apoE KO (B), and
previously hyperglycemic apoE KO mice (C). ABDOM, abdominal;
THOR, thoracic. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
TABLE 2
mRNA expression of NFB-p65, MCP-1, and VCAM in control
apoE KO, diabetic apoE KO, and previously hyperglycemic apoE
KO mice
n
NFB-
p65 MCP-1 VCAM-1
Control apoE KO
(NG3NG) 5 1.0 	 0.2 1.1 	 0.2 1.0 	 0.2
Diabetic apoE KO
(HG3HG) 5 2.5 	 0.9* 3.2 	 1.1* 3.2 	 0.5*
Previously
hyperglycemic apoE
KO (HG3NG) 4 2.7 	 1.1* 3.7 	 0.9* 1.9 	 0.06*†
Data are means 	 SE. *P  0.05 compared with control apoE KO
group; †P  0.05 compared with diabetic apoE KO group.
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identiﬁcation of a long-term impact on cardiovascular
events as a result of previous periods of altered glycemic
control in the DCCT has emphasized this phenomenon of
“metabolic memory” (2). More recently, the long-term
outcomes, in particular cardiovascular outcomes, from the
UKPDS suggest that the period of intensive glycemic
control that occurred more than a decade ago and initially
did not demonstrate statistically signiﬁcant reductions in
macrovascular disease, now shows clear beneﬁts on a
range of cardiovascular end points including mortality
(30). It remains to be determined as to the underlying
explanation for these persistent, ongoing injurious effects
to diabetic vessels as a result of previous hyperglycemia.
However, the recent demonstration by several groups of
various epigenetic changes as a result of hyperglycemia
(3,26) and, in particular in this study, certain changes in
enzymes involved in histone methylation and demethyl-
ation emphasizes the potential long-term effects of glucose
on processes linked to gene expression. This study fo-
cused on histone methylation changes in response to
transient hyperglycemia, illustrating that distinct H3K4
and H3K9 methylation patterns on the NFB-p65 gene
coexist to regulate gene expression, and these methyl-
marks are probably associated with the activity of methyl-
writing and -erasing enzymes on the promoter.
Interestingly, other evidence suggests that H3K4m2 is
increased on genes activated by hyperglycemia, which was
recently postulated to be inversely correlated with LSD1
(26). Although these distinguishable results indicate a
complicated and somewhat contradictory set of experi-
mental data, we cannot exclude that these distinct differ-
ences indicate functional specialization of H3 enzymes in
the various vascular cell populations.
To further explore the potential in vivo relevance of the
changes associated with p65 gene expression, we used an
extensively characterized model of diabetes-associated
atherosclerosis (11,27). In this model, a subgroup of
diabetic animals lost their severe hyperglycemia, as has
previously been reported after injection of streptozotocin
in various rodent models of diabetes (28,31,32). Despite a
reduction in plasma glucose and lipid levels at death in
these previously hyperglycemic mice, p65 gene upregula-
tion persisted, as did the increase in gene expression of
various NFB-dependent proteins, MCP-1, and VCAM-1.
Furthermore, the sustained increase in these pro-inﬂam-
matory molecules was associated with increased athero-
sclerosis in these mice with prior hyperglycemia. These
changes are consistent with this model, exhibiting macro-
vascular disease as a result of “metabolic memory.”
Thus, it appears that periods of transient or prior
hyperglycemia lead to various methylation and demethyl-
ation events that, when integrated, have an impact on gene
activity. These events lead to sustained activation of
pro-inﬂammatory pathways, which are likely to participate
in the progression of diabetic complications. Further un-
derstanding of the chromatin remodeling events and how
they are linked to ongoing vascular changes in diabetes
should lead to better strategies to reduce the burden of
diabetes complications.
ACKNOWLEDGMENTS
The authors acknowledge grant support from the Juvenile
Diabetes Research Foundation International (JDRF), the
Diabetes Australia Research Trust, the National Health
and Medical Research Council (NHMRC) of Australia, and
the National Heart Foundation of Australia. A.E.-O.,
M.E.C., and A.C.C. are recipients of a Career Development
Award, a Senior Principal Research Fellowship, and a
Doherty Post-Doctoral fellowship, respectively, from the
NHMRC. C.T. and A.B. are recipients of fellowships from
the JDRF and the Foundation for Polish Science.
No potential conﬂicts of interest relevant to this article
were reported.
We thank Peter L. Jones (University of Illinois at Urba-
na-Champaign) for the Set7 antibody and Audrey Koitka
and Anna Watson for their technical assistance with the in
vivo studies.
REFERENCES
1. Epidemiology of Diabetes Interventions and Complications (EDIC) Study
Group. Sustained effect of intensive treatment of type 1 diabetes mellitus
on development and progression of diabetic nephropathy. JAMA 2003;290:
2159–2167
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ,
Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular
disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
3. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper
ME, Brownlee M. Transient high glucose causes persistent epigenetic
changes and altered gene expression during subsequent normoglycemia. J
Exp Med 2008;205:2409–2417
4. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med
2008;359:1618–1620
5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M,
Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L,
Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B,
Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose
control and vascular outcomes in patients with type 2 diabetes. N Engl
J Med 2008;358:2560–2572
6. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB,
Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstﬁeld JL,
Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering
in type 2 diabetes. N Engl J Med 2008;358:2545–2559
7. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of ﬁbronectin
induced by diabetes or high glucose: phenomenon with a memory. Proc
Natl Acad SciUSA1990;87:404–408
8. Mack CP. An epigenetic clue to diabetic vascular disease. Circ Res
2008;103:568–570
9. Okabe J, Eguchi A, Wadhwa R, Rakwal R, Tsukinoki R, Hayakawa T,
Nakanishi M. Limited capacity of the nuclear matrix to bind telomere
repeat binding factor TRF1 may restrict the proliferation of mortal human
ﬁbroblasts. Hum Mol Genet 2004;13:285–293
10. Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid
ﬁbroblasts with respect to oncogene-mediated transformation. Proc Natl
Acad SciUSA2003;100:13567–13572
11. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM,
Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis
by angiotensin-converting enzyme inhibition in diabetic apolipoprotein
E-deﬁcient mice. Circulation 2002;106:246–253
12. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT,
Jandeleit-Dahm K, Cooper ME, Forbes JM. Interactions between renin
angiotensin system and advanced glycation in the kidney. J Am Soc
Nephrol 2005;16:2976–2984
13. Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor
IA, Blackburn GM, Gamblin SJ. Structure and catalytic mechanism of the
human histone methyltransferase SET7/9. Nature 2003;421:652–656
14. Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P,
Zhang Y. Puriﬁcation and functional characterization of a histone H3-lysine
4-speciﬁc methyltransferase. Mol Cell 2001;8:1207–1217
15. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3:
intricacy of writing and reading a single epigenetic mark. Mol Cell
2007;25:15–30
16. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP,
Nakatani Y, Shi Y. Coordinated histone modiﬁcations mediated by a CtBP
co-repressor complex. Nature 2003;422:735–738
17. Metzger E, Schule R. The expanding world of histone lysine demethylases.
Nat Struct Mol Biol 2007;14:252–254
D. BRASACCHIO AND ASSOCIATES
DIABETES, VOL. 58, MAY 2009 123518. Trojer P, Reinberg D. Histone lysine demethylases and their impact on
epigenetics. Cell 2006;125:213–217
19. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH,
Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone
marks to promote androgen-receptor-dependent transcription. Nature
2005;437:436–439
20. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi
Y. Histone demethylation mediated by the nuclear amine oxidase homolog
LSD1. Cell 2004;119:941–953
21. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, Vogler
C, Schneider R, Gunther T, Buettner R, Metzger E, Schule R. Cooperative
demethylation by JMJD2C and LSD1 promotes androgen receptor-depen-
dent gene expression. Nat Cell Biol 2007;9:347–353
22. Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH,
Tempst P, Zhang Y. Histone demethylation by a family of JmjC domain-
containing proteins. Nature 2006;439:811–816
23. Lan F, Zaratiegui M, Villen J, Vaughn MW, Verdel A, Huarte M, Shi Y, Gygi
SP, Moazed D, Martienssen RA. S. pombe LSD1 homologs regulate
heterochromatin propagation and euchromatic gene transcription. Mol
Cell 2007;26:89–101
24. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P,
Wong J, Zhang Y. The transcriptional repressor JHDM3A demethylates
trimethyl histone H3 lysine 9 and lysine 36. Nature 2006;442:312–316
25. Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P,
Wong J, Zhang Y. JHDM2A, a JmjC-containing H3K9 demethylase, facili-
tates transcription activation by androgen receptor. Cell 2006;125:483–495
26. Reddy MA, Villeneuve LM, Wang M, Lanting L, Natarajan R. Role of the
lysine-speciﬁc demethylase 1 in the proinﬂammatory phenotype of
vascular smooth muscle cells of diabetic mice. Circ Res 2008;103:615–
623
27. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H,
McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ.
Recipes for creating animal models of diabetic cardiovascular disease.
Circ Res 2007;100:1415–1427
28. Kennedy JM, Zochodne DW. Experimental diabetic neuropathy with
spontaneous recovery: is there irreparable damage? Diabetes 2005;54:830–
837
29. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-
Dahm KA. Irbesartan but not amlodipine suppresses diabetes-associated
atherosclerosis. Circulation 2004;109:1536–1542
30. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up
of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:
1577–1589
31. Hartmann K, Besch W, Zuhlke H. Spontaneous recovery of streptozotocin
diabetes in mice. Exp Clin Endocrinol 1989;93:225–230
32. Lake SP, Chamberlain J, Husken P, Bell PR, James RF. In vivo assessment
of isolated pancreatic islet viability using the streptozotocin-induced
diabetic nude rat. Diabetologia 1988;31:390–394
HYPERGLYCEMIC MEMORY AND THE H3-LYSINE TAIL
1236 DIABETES, VOL. 58, MAY 2009